Health Canada Approves Reduced Post-Treatment Monitoring for BMS's BREYANZI CAR T Therapy
Key Insights
Health Canada has updated the BREYANZI product monograph, reducing the required proximity to a treatment centre from 28 days to 14 days post-infusion for eligible patients.
Driving restrictions following BREYANZI infusion have been shortened from eight weeks to four weeks, offering greater flexibility for recovering patients.
The updates are supported by safety data from seven clinical trials involving 691 patients and real-world registry data from 877 patients treated with BREYANZI.
Health Canada has approved updates to the Canadian product monograph for Bristol Myers Squibb (search)'s BREYANZI (lisocabtagene maraleucel), a CD19 (search)-directed chimeric antigen receptor (CAR) T cell therapy, reducing the duration of certain post-treatment monitoring and activity restrictions for eligible patients following infusion. The announcement was made by Bristol Myers Squibb Canada on June 17, 2026.
The revised guidance shortens the recommended period during which patients must remain in close proximity to a specialized treatment centre from 28 days to 14 days following infusion. Additionally, driving restrictions have been reduced from eight weeks to four weeks. Clinical decisions regarding patient discharge and ongoing monitoring will continue to be determined by the treating healthcare professional based on individual patient needs.
Evidence Supporting the Regulatory Update
The product monograph changes are underpinned by a growing body of evidence indicating that the risk of treatment-related adverse events decreases significantly after the first 14 days following infusion. The updated guidance draws on safety data from seven clinical trials involving 691 patients, as well as real-world registry data from 877 patients treated with BREYANZI.
"Clinical experience with BREYANZI has continued to expand in both clinical trial and real-world settings, contributing to a deeper understanding of how patients with relapsed or refractory large B-cell lymphomas (search) can be appropriately monitored following treatment," said Dr. Michael Kennah, a hematologist specializing in cellular therapies at The Ottawa Hospital. "CAR T cell therapy has transformed outcomes for many patients facing these aggressive lymphomas, and these updates reflect the growing body of evidence and clinical experience informing post-treatment patient management."
Impact on Patients and Caregivers
The revised monitoring requirements are expected to create greater flexibility in follow-up care, potentially alleviating capacity pressures at specialized CAR T treatment centres by enabling appropriate patients to transition back to community-based care sooner. For patients and their families, the changes address significant logistical and emotional challenges.
"For patients and their families or caregivers already facing the emotional weight of a cancer diagnosis, the need to travel to receive CAR T cell therapy and remain close to a specialized treatment centre for extended periods can add another layer of stress, as well as logistical and financial strain during an already challenging time," said Antonella Rizza, Chief Executive Officer of Lymphoma Canada. "The potential for eligible patients to transition home sooner following treatment may help lessen these emotional and practical demands on Canadian patients and their caregivers."
About BREYANZI
BREYANZI is a personalized cell therapy manufactured using a patient's own white blood cells. These cells are collected from the patient's blood and sent to a specialized facility, where they are reprogrammed to recognize lymphoma cells. Once returned to the patient's body, the modified cells are designed to identify and attack lymphoma cells. BREYANZI is approved in Canada for certain adults with relapsed or refractory large B-cell lymphomas (search), including second-line use in eligible patients whose disease is refractory to or relapses within 12 months of first-line chemoimmunotherapy.
"We believe innovation includes not only advancing transformational therapies but also supporting improvements in the overall treatment experience for patients, caregivers and healthcare teams," said Elaine Phillips, General Manager, Bristol Myers Squibb (search) Canada. "These updates reflect the growing experience with BREYANZI and represent continued progress in how CAR T cell therapy may be delivered and experienced by patients in Canada and reinforce our ongoing commitment to advancing the science of cellular therapy to support patients across lymphomas and other hematologic malignancies."
Dr. Kennah further noted that the revised timelines "may support greater flexibility during the post-treatment period and help lessen the logistical and emotional burden associated with care, while maintaining individualized oversight and patient safety."